Expression vector for expressing recombinant Hucas12a protein, recombinant engineering bacterium and application of recombinant engineering bacterium

Through the multi-step purification method of using MBP-TEV tag and HIS tag in HuCas12a protein expression, the problems of low yield and low purity in the prior art were solved, and the efficient and simple acquisition of high-purity Hucas12a protein was achieved, which improved its Application value in the field of gene editing.

CN119082162APending Publication Date: 2024-12-06LICHI BIOLOGICAL PROD (CHONGQING) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411462950.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-19
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

In the prior art, the purification method of HuCas12a protein has problems with low yield and low purity, which limits its application in the field of gene editing.

Method used

Using expression vectors containing MBP-TEV tags and HIS tags, expression was induced by E. coli such as Rosetta2 (DE3), and multi-step purification was performed using Ni-NTA chromatography column and ion column, including enzyme removal of MBP tags and gradient elution. High purity of Hucas12a protein was obtained.

Benefits of technology

It achieves efficient and simple acquisition of high-purity Hucas12a protein, which enhances its application value in the field of gene editing and overcomes the problems of low yield and low purity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082162A_ABST
    Figure CN119082162A_ABST
Patent Text Reader

Abstract

The invention provides a Hucas12a recombinant protein expression vector, a recombinant engineering bacterium and a simple, convenient and efficient purification method, solves the problems of low yield, low purity and the like in the existing method, and has important scientific research and application values.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, specifically to the field of gene editing technology, and in particular to a method for purifying recombinant Hucas12a protein and an application thereof. Background Art

[0002] HuCas12a (humanized Cas12a) is a new gene editing tool derived from the CRISPR-Cas system. Cas12a was originally discovered in a bacterium called Acidaminococcus and quickly attracted the attention of the scientific community for its unique properties and versatility.

[0003] The CRISPR-Cas system is essentially an immune defense mechanism of bacteria and archaea that can recognize and destroy invading viral DNA. Cas12a (formerly known as Cpf1) is a variant of this system and has some unique advantages over the more well-known Cas9. First, Cas12a can recognize and cut different PAM sequences (PAM, or protospacer adjacent motif), which provides greater flexibility for its application in different genomes. Second, Cas12a cuts in a way that produces a 5' overhang, which provides more possibilities for subsequent DNA repair.

[0004] However, Cas12a in its original form can trigger an immune response, making its use in humans challenging. To address this, researchers developed HuCas12a, a humanized Cas12a enzyme designed to reduce immunogenicity when used in mammalian cells. By introducing sequence and structural modifications that are more similar to human proteins, HuCas12a can function more efficiently in mammalian cells while reducing the risk of potential immune responses.

[0005] The development of HuCas12a has opened up new prospects for gene therapy, gene function research, and other gene editing applications. Its potential applications include treating genetic diseases, studying gene function, and developing new genome editing technologies. As research on the CRISPR-Cas system continues to deepen, HuCas12a is expected to become an important member of the next generation of gene editing tools and play a greater role in the fields of medicine and biotechnology. Summary of the invention

[0006] The object of the present invention is to provide a method for purifying recombinant Hucas12a protein and its application. The method is simple in process, the obtained target protein has high purity and high cleavage activity. The present invention provides an efficient method for expressing and purifying recombinant Hucas12a protein, comprising the following steps:

[0007] An expression vector for expressing a recombinant Hucas12a protein, comprising a gene encoding an MBP-TEV tag, a gene encoding the Hucas12a protein, and a backbone plasmid containing a HIS tag; the nucleotide sequence of the gene encoding the Hucas12a protein is SEQ ID NO: 1; the nucleotide sequence of the gene encoding the MBP-TEV tag is SEQ ID NO: 2.

[0008] In one embodiment according to the present invention, the backbone vector is selected from PET 28a and PGEX-6P; preferably pET28a(+).

[0009] The present invention also provides a recombinant engineered bacterium for expressing recombinant Hucas12a protein, which comprises a host bacterium and the above-mentioned expression vector.

[0010] In one embodiment of the present invention, the host bacteria is Escherichia coli; preferably, the host bacteria is Origami 2 (DE3), Rosetta 2 (DE3), BL21 (DE3), BL21 (DE3)

[0011] PlysS, Transetta (DE3) or Tuner (DE3); preferably Rosetta 2 (DE3).

[0012] In another aspect, the present invention provides use of the above-mentioned expression vector or recombinant engineered bacteria in preparing recombinant Hucas12a protein.

[0013] The present invention further provides a method for preparing a recombinant Hucas12a protein, characterized in that it comprises:

[0014] 1) Introducing the above expression vector into a host bacterium to induce expression; or inducing the above recombinant engineered bacterium to express, to obtain a bacterium expressing Hucas12a;

[0015] 2) breaking the bacteria and isolating to obtain the MBP-TEV-Hucas12a protein solution;

[0016] 3) Purification by Ni-NTA chromatography column to obtain the protein containing MBP-TEV-Hucas12a;

[0017] 4) Enzyme digestion: using tobacco etch virus protease to digest and remove the MBP tag;

[0018] 5) Purification by ion column to obtain Hucas12a protein.

[0019] In one embodiment of the present invention, step 2) comprises: mixing and suspending the Hucas12a expressing bacteria collected in step 1) with a balancing solution, precooling and high pressure breaking the bacteria, high speed centrifugation, collecting the supernatant, and obtaining a protein solution; the balancing solution comprises 50 mM HEPES, 100 mM KCl, 10% glycerol, pH 7.5;

[0020] Preferably, high pressure of 700-800 mPa and high-speed centrifugation are used to break the bacteria and obtain the supernatant.

[0021] In one embodiment of the present invention, the Ni-NTA chromatography column purification described in step 3) is achieved by a method comprising the following steps:

[0022] The Ni-NTA chromatography column was alternately rinsed with pure water and equilibration solution for 5-10 column volumes, the protein solution collected in step 2) was added, and the purified protein was collected and eluted with an eluent containing imidazole; the eluent contained 50 mM HEPES, 100 mM KCl, 20-500 mM imidazole, 10% glycerol, pH 7.5;

[0023] Preferably, the Ni-NTA chromatography purification filler is HisSep Ni-NTA Agarose Resin; the filler dosage is 100 mL per 100 g wet weight of broken bacteria, and the incubation conditions are: 4° C., 2 h.

[0024] In one embodiment of the present invention, the elution conditions in step 3) are: 50 mM HEPES, 200-500 mM KCl, 10% glycerol, pH 7.5, gradient elution.

[0025] In one embodiment of the present invention, the ion column purification described in step 5) is achieved by a method comprising the following steps:

[0026] After washing the ion column three times with pure water and equilibrium solution alternately, add step 4) to collect the protein solution, then wash away impurities with 200-400mM KCl solution, and then elute with 500mM KCl solution to collect the purified Hucas12a protein; preferably, the filler is Capto TM S ImpAct The present invention first provides a method.

[0027] The beneficial effects of the above technical solution of the present invention are as follows:

[0028] The present invention provides a simple and efficient method for expressing and purifying Hucas12a recombinant protein, which overcomes the problems of low yield and low purity in the existing methods and has important scientific research and application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is the result of Ni-NTA purification and identification of pET28-6His-MBP-TEV-Hucas12a protein expression;

[0030] Figure 2 This is the result of Hucas12a protease cleavage of MBP tag;

[0031] Figure 3 This is the result of ion column purification after Hucas12a protease cleavage;

[0032] Figure 4 This is a diagram showing the results of identifying the activity of Hucas12a protein. DETAILED DESCRIPTION

[0033] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.

[0034] Unless otherwise specified, all reagents used in this example were of analytical grade, and the progress of all chemical reactions was detected by thin layer chromatography.

[0035] The invention clones and expresses the Hucas12a gene, constructs it into a pET28 plasmid, and induces recombinant expression in Rosetta2 (DE3) under 1 mM IPTG and 37°C conditions, then breaks the bacteria by high pressure centrifugation, and purifies the prepared recombinant protein by a Ni-NTA chromatography column.

[0036] The present invention is described in detail below with reference to the accompanying drawings and embodiments.

[0037] Materials and reagents

[0038] 1. Main Reagents

[0039] Kanamycin Sulfate Maclean Chloramphenicol Maclean IPTG (isopropyl-β-D-thiogalactopyranoside) Biosharp 12% PAGE Color Gel Quick Preparation Kit Biosharp <![CDATA[Capto TM S ImpAct Ion Column]]> Cytiva His-Sep Ni-NTA Agaroses Resin Yeasen

[0040] 2. Main instruments and equipment

[0041] JFZD-200B Oscillator Hangzhou Jingpei Instrument Technology Co., Ltd. High-speed refrigerated centrifuge Lu Xiangyi Ultrasonic cell disruptor Ningbo Xinzhi Biotechnology Co., Ltd. Chromatography AKTA pure150 Full wavelength microplate reader Thermo Scientific Imager Tanon High pressure homogenizer Ningbo Xinzhi Biotechnology Co., Ltd.

[0042] Example 1 Cloning and construction of Hucas12a gene

[0043] 1) Construction of pET28-6His-MBP-TEV-Hucas12a vector

[0044] The Hucas12a CDS nucleotide sequence is shown in SEQ ID NO.1. The above sequence was synthesized by full gene synthesis, and the TEV protease cleavage site and MBP tag were added to the front section of the Hucas12a nucleotide sequence to obtain the MBP-TEV-Hucas12a coding gene with a nucleotide sequence of SEQID NO: 2. It was cloned into the pET28a plasmid to construct the pET28-6His-MBP-TEV-Hucas12a vector, and the pET28-6His-MBP-TEV-Hucas12a fusion protein coding gene was 10706bp in length. The expression used the inherent T7 promoter, lac operator, RBS and T7 terminator on the pET28 vector, and the protein expression could be regulated by isopropyl-β-D-thiogalactopyranoside (IPTG).

[0045] 2) The recombinant plasmid was transformed into the expression strain Rosetta2 (DE3) to obtain the recombinant Escherichia coli pET28 / Hucas12a / Rosetta2 (DE3) that can express Hucas12a.

[0046] The nucleotide sequence of the gene encoding the Hucas12a protein is shown in SEQ ID NO: 1:

[0047]

[0048]

[0049]

[0050] The nucleotide sequence of the gene encoding the MBP-TEV tag is shown in SEQ ID NO: 2:

[0051]

[0052]

[0053]

[0054] Example 2 Inducible expression of Hucas12a protein

[0055] 1) Activation of bacteria: The candidate protein expression bacteria pET28 / Hucas12a / Rosetta2 (DE3) stored at -80°C were inoculated at a ratio of 1:1000 for activation, i.e., 10 μL of glycerol bacterial solution was added to 10 mL of LB medium containing Kana and CHL resistance, and cultured overnight at 37°C, 200 rpm for 16 h.

[0056] 2) Secondary activation induction: Inoculate bacteria at a ratio of 1:100 for secondary activation. Take 200 μL of overnight bacterial solution and add it to 20 mL of LB medium containing Kana and CHL resistance. Incubate at 37°C for 4 h at 180 rpm. Secondary activation until OD 600 When the pH value is 0.6, add IPTG to a final concentration of 1 mM, place in a shaker at 37°C, 180 rpm for 3 h. (Preparation of IPTG solution: dissolve 2.38 g IPTG in 10 mL Grade I water, filter with a 0.22 μm sterile filter after complete dissolution).

[0057] 3) Take out the induced expression bacterial solution, centrifuge at 4°C, 6000 rpm for 15 min, discard the supernatant, add 1-2 mL of balancing solution (50 mM HEPES, 100 mM KCl, 10% glycerol, pH 7.5), resuspend and mix, ultrasonically disrupt the bacteria for 15 min, collect the disrupted solution, centrifuge at 4°C, 12000 rpm for 15 min, and separate the supernatant and precipitate.

[0058] 4) Process the supernatant and precipitate: take 20 μL of supernatant and add 5 μL of 5× protein loading buffer, boil for 5 min, and then centrifuge at 14000 rpm for 3 min; add 30 μL of equilibration solution to resuspend the bacteria in the precipitate, take 20 μL of the resuspended bacteria solution and add 5 μL of 5× protein loading buffer, boil for 5 min, and centrifuge at 14000 rpm for 3 min.

[0059] 5) Pour 12% concentrated gel into the gel plate, add distilled water to flatten the gel, let it stand at room temperature for 30 minutes to solidify, pour out the distilled water on the upper layer, and then pour in 12% separation gel, immediately insert the comb, and let it stand at room temperature for 30 minutes to solidify for use. Take 10μL of the treated supernatant and precipitate, respectively, and perform SDS-PAGE electrophoresis. The voltage is first 80v for 30min, then adjusted to 180v. After electrophoresis for 1-2h, take out the gel, place it in instant blue staining solution for shaking and staining, and then place it in water for shaking and decolorization. Observe the results under the imaging system. Hucas12a is a soluble protein (the results are shown in Figure 1 shown).

[0060] Example 3 Preparation of Hucas12a recombinant protein

[0061] 1) Amplification and culture to obtain protein: 400 μL of pET28 / Hucas12a / Rosetta2 (DE3) bacterial solution stored in a 4°C refrigerator was added to 20 mL of LB medium containing Kana and CHL resistance for primary activation, and cultured at 200 rpm and 37°C for 4 hours. Then, 20 mL of the primary activated bacterial solution was added to 2000 mL of LB medium containing Kana and CHL resistance for secondary activation, and cultured at 37°C for 4 hours. 2 mL of IPTG (mother solution concentration is 1 M) was added to induce at 180 rpm in a 37°C shaker for 3 hours, and then centrifuged at 4°C and 12000 rpm for 15 minutes to collect the bacteria. 50 mL of balancing solution was added to resuspend the bacteria, and the bacterial solution was high-pressure lysed (pressure was 700-800 mpa), and the lysed solution was collected.

[0062] 2) Binding of protein to filler: After breaking the bacteria, the solution was centrifuged at 12000rpm, 50min, and 4℃, and the supernatant was taken and purified using Akta pure 150. The impurities were washed with 5 times the column volume of 20mM imidazole and 5 times the column volume of 50mM imidazole, and samples were taken. The Hucas12a protein was eluted with 5 times the column volume of 200mM imidazole-500mM imidazole, and samples were taken for SDS-PAGE electrophoresis. Finally, the filler was washed with 500mM imidazole, rinsed with pure water, and stored in 20% ethanol.

[0063] 3) Enzyme digestion: Enzyme digestion was performed using tobacco etch virus protease to remove the MBP tag from the HuCas12a protein with the MBP tag (the result is shown in FIG. Figure 2 shown).

[0064] 4) Purify the target protein collected after enzyme digestion and use Capto TM S ImpAct ion column purification; elution conditions: 200mM, 300mM, 400mM saline solution for washing, 500mM saline solution for elution and purification of HuCas12a protein. Each gradient collects about 2 column volumes (depending on the UV absorption peak of the chromatograph), and each gradient sample is marked for electrophoresis detection (the results are shown in Figure 2). Figure 3 shown).

[0065] 5) Protein concentration and buffer replacement: The eluted protein solution was dialyzed (dialysis bag: molecular weight 14,000). The dialysate composition includes: 50mM NaCl, 20mM sodium acetate, 0.1mM EDTA, 0.1mM DTT, 0.5mM PMSF, 50% glycerol, stirred overnight at 4°C. The protein was taken out the next day to determine the protein concentration. Finally, 10mg of HuCas12a protein was obtained per liter of bacterial solution, with a purity of more than 90%.

[0066] 6) Protein activity assay: While Hucas12a recognizes and cuts the target double-stranded DNA (reaction substrate), its high-efficiency cutting activity of single-stranded DNA (ssDNA) of any sequence is activated. By designing probes with fluorescent markers or other small molecule markers at both ends, the signal amplification of DNA detection by CRISPR / Cas12a is achieved, and the cutting activity of Hucas12a recombinant protein is measured using real-time fluorescence method, such as Figure 4 shown.

[0067] Reaction system:

[0068] Ingredient name Reaction volume / final concentration 10×Reaction Buffer 1 1× Hucas12a 2μL gRNA 50nmol Fluorescent probes 40nM <![CDATA[H 2 The]]> Add the above to 48 μL Reaction substrate 2μL

[0069] The results of fluorescence detection showed that the strong positive reaction curve reached the plateau in 10-15 minutes.

[0070] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. An expression vector for expressing recombinant Hucas12a protein, characterized in that: It comprises a gene encoding an MBP-TEV tag, a gene encoding a Hucas12a protein and a backbone plasmid containing a HIS tag; the nucleotide sequence of the gene encoding the Hucas12a protein is SEQ ID NO: 1; the nucleotide sequence of the gene encoding the MBP-TEV tag is SEQ ID NO:

2.

2. The expression vector according to claim 1, characterized in that The backbone plasmid is selected from PET 28a and PGEX-6P; preferably pET28a(+).

3. A recombinant engineered bacterium for expressing recombinant Hucas12a protein, characterized in that: It comprises a host bacterium and the expression vector as claimed in claim 1 or 2.

4. The recombinant engineered bacterium according to claim 3, characterized in that The host bacteria is Escherichia coli; preferably, the host bacteria is Origami 2 (DE3), Rosetta 2 (DE3), BL21 (DE3), BL21 (DE3) PlysS, Transetta (DE3) or Tuner (DE3); preferably Rosetta 2 (DE3).

5. Use of the expression vector according to claim 1 or 2 or the recombinant engineered bacteria according to claim 3 or 4 in preparing recombinant Hucas12a protein.

6. A method for preparing a recombinant Hucas12a protein, characterized in that: include: 1) Introducing the expression vector as claimed in claim 1 or 2 into a host bacterium to induce expression; or inducing expression of the recombinant engineered bacterium as claimed in claim 3 or 4 to obtain a bacterium expressing Hucas12a; 2) breaking the bacteria and isolating to obtain the MBP-TEV-Hucas12a protein solution; 3) Purification by Ni-NTA column to obtain the protein containing MBP-TEV-Hucas12a; 4) Enzyme digestion: using tobacco etch virus protease to digest and remove the MBP tag; 5) Purification by ion column to obtain Hucas12a protein.

7. The preparation method according to claim 6, characterized in that: Step 2) comprises: mixing and suspending the Hucas12a-expressing bacteria collected in step 1) with a balancing solution, precooling and breaking the bacteria with high pressure, centrifuging at high speed, collecting the supernatant, and obtaining a protein solution; the balancing solution comprises 50 mM HEPES, 100 mM KCl, 10% glycerol, pH 7.5; Preferably, high pressure of 700-800 mPa and high-speed centrifugation are used to break the bacteria and obtain the supernatant.

8. The preparation method according to claim 6 or 7, characterized in that: The Ni-NTA chromatography column purification described in step 3) is achieved by a method comprising the following steps: The Ni-NTA chromatography column was alternately rinsed with pure water and equilibration solution for 5-10 column volumes, the protein solution collected in step 2) was added, and the purified protein was collected and eluted with an eluent containing imidazole; the eluent contained 50 mM HEPES, 100 mM KCl, 20-500 mM imidazole, 10% glycerol, pH 7.5; Preferably, the Ni-NTA chromatography purification filler is HisSep Ni-NTA Agarose Resin; the filler dosage is 100 mL per 100 g wet weight of broken bacteria, and the incubation conditions are: 4° C., 2 h.

9. The preparation method according to any one of claims 6 to 8, characterized in that: The elution conditions in step 3) are: 50 mM HEPES, 200-500 mM KCl, 10% glycerol, pH 7.5, gradient elution.

10. The preparation method according to any one of claims 6 to 9, characterized in that: The ion column purification described in step 5) is achieved by a method comprising the following steps: After washing the ion column three times with pure water and equilibrium solution alternately, add step 4) to collect the protein solution, then wash away impurities with 200-400mM KCl solution, and then elute with 500mM KCl solution to collect the purified Hucas12a protein; preferably, the filler is Capto TM S ImpAct.